Acharya Balkrishna, Subarna Pokhrel* and Anurag Varshney Pages 1 - 8 ( 8 )
Introduction: Cycloxygenase I (COX I) plays an important role in the pathogenesis of atherothrombosis. Therefore, there is need of anti-platelet aggregation drugs that decrease thrombus formation.
Methods: Molecular docking of the phytochemicals (flavonoids, alkaloids, terpenoids and lignans) showed that their inhibitory activity towards COX I mainly depends on hydrogen bonds between the hydroxyl groups of the polyphenol ligands and the binding sites, πcation/anion, π-sigma bond, π-alkyl, and π-π T shaped interactions that stabilize the ligand within the active site.
Results: Alkaloids are superior over the others to develop as optimal inhibitor compounds of human COX I in terms of ligand efficiency.
Conclusion: Which fall within the criteria of orally efficacious drugs, and could pave a way for lead antiplatelet drug discovery and subsequent development.
Antiplatelet activity, flavonoids, alkaloids, terpenoids, lignans, cycloxygenase I, molecular docking.
Drug Discovery and Development Division, Patanjali Research Institute, Patanjali Research Foundation Trust, Roorkee-Haridwar Road, Haridwar-249405, Uttarakhand, Drug Discovery and Development Division, Patanjali Research Institute, Patanjali Research Foundation Trust, Roorkee-Haridwar Road, Haridwar-249405, Uttarakhand, Drug Discovery and Development Division, Patanjali Research Institute, Patanjali Research Foundation Trust, Roorkee-Haridwar Road, Haridwar-249405, Uttarakhand